Literature DB >> 34050678

Prenatal histological, cellular, and molecular anomalies in trisomy 21 lung.

Soula Danopoulos1, Soumyaroop Bhattacharya2, Gail Deutsch3, Lina R Nih1, Chris Slaunwhite2, Thomas J Mariani2, Denise Al Alam1.   

Abstract

Down syndrome (DS), also known as trisomy 21 (T21), is the most common human chromosomal anomaly. Although DS can affect many organ systems, lung and heart disease are the leading causes of death. An abundance of existing data suggests that lung abnormalities originate postnatally in DS. However, a single report of branching insufficiency in DS has inferred a potential prenatal origin. The histology of T21 fetal lungs (n = 15) was assessed by an experienced pathologist. Spatial differences in cellular phenotypes were examined using immunohistochemistry (IHC). Comprehensive gene expression in prenatal T21 lungs (n = 19), and age-matched controls (n = 19), was performed using high-throughput RNA sequencing (RNAseq) and validated by RT-qPCR. Histopathological abnormalities were observed in approximately half of T21 prenatal lung samples analyzed, which included dilated terminal airways/acinar tubules, dilated lymphatics, and arterial wall thickening. IHC for Ki67 revealed significant reductions in epithelial and mesenchymal cell proliferation, predominantly in tissues displaying pathology. IHC demonstrated that airway smooth muscle was reduced and discontinuous in the proximal airway in conjunction with reduced SOX2. RNAseq identified 118 genes significantly dysregulated (FDR < 0.05) in T21 lung when unadjusted and 316 genes when adjusted for age. Ontology analysis showed that IFN pathway genes were appreciably upregulated, whereas complement and coagulation cascades and extracellular matrix pathway genes were downregulated. RT-qPCR confirmed the changes in genes associated with these pathways in prenatal T21 lungs. Our data demonstrate that specific histological, cellular, and molecular abnormalities occur prenatally in different compartments of human T21 lung, which could be representative of premature stage progression.
© 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. © 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  Down syndrome; RNAseq; extracellular matrix; histopathology; lung development; trisomy 21; type I interferon

Mesh:

Year:  2021        PMID: 34050678      PMCID: PMC9109699          DOI: 10.1002/path.5735

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   9.883


  51 in total

Review 1.  Neurogenesis impairment: An early developmental defect in Down syndrome.

Authors:  Fiorenza Stagni; Andrea Giacomini; Marco Emili; Sandra Guidi; Renata Bartesaghi
Journal:  Free Radic Biol Med       Date:  2017-07-27       Impact factor: 7.376

Review 2.  What people with Down Syndrome can teach us about cardiopulmonary disease.

Authors:  Kelley L Colvin; Michael E Yeager
Journal:  Eur Respir Rev       Date:  2017-02-21

3.  Conditional gene inactivation reveals roles for Fgf10 and Fgfr2 in establishing a normal pattern of epithelial branching in the mouse lung.

Authors:  Lisa L Abler; Suzanne L Mansour; Xin Sun
Journal:  Dev Dyn       Date:  2009-08       Impact factor: 3.780

4.  Domains of genome-wide gene expression dysregulation in Down's syndrome.

Authors:  Audrey Letourneau; Federico A Santoni; Ximena Bonilla; M Reza Sailani; David Gonzalez; Jop Kind; Claire Chevalier; Robert Thurman; Richard S Sandstrom; Youssef Hibaoui; Marco Garieri; Konstantin Popadin; Emilie Falconnet; Maryline Gagnebin; Corinne Gehrig; Anne Vannier; Michel Guipponi; Laurent Farinelli; Daniel Robyr; Eugenia Migliavacca; Christelle Borel; Samuel Deutsch; Anis Feki; John A Stamatoyannopoulos; Yann Herault; Bas van Steensel; Roderic Guigo; Stylianos E Antonarakis
Journal:  Nature       Date:  2014-04-17       Impact factor: 49.962

5.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update.

Authors:  Maxim V Kuleshov; Matthew R Jones; Andrew D Rouillard; Nicolas F Fernandez; Qiaonan Duan; Zichen Wang; Simon Koplev; Sherry L Jenkins; Kathleen M Jagodnik; Alexander Lachmann; Michael G McDermott; Caroline D Monteiro; Gregory W Gundersen; Avi Ma'ayan
Journal:  Nucleic Acids Res       Date:  2016-05-03       Impact factor: 16.971

Review 6.  Primary care for children and adolescents with Down syndrome.

Authors:  Melissa A Davidson
Journal:  Pediatr Clin North Am       Date:  2008-10       Impact factor: 3.278

7.  Human lung branching morphogenesis is orchestrated by the spatiotemporal distribution of ACTA2, SOX2, and SOX9.

Authors:  Soula Danopoulos; Irving Alonso; Matthew E Thornton; Brendan H Grubbs; Saverio Bellusci; David Warburton; Denise Al Alam
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-09-28       Impact factor: 5.464

8.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

Review 9.  The burden of respiratory syncytial virus (RSV) associated acute lower respiratory infections in children with Down syndrome: A systematic review and meta-analysis.

Authors:  Markus Chan; John J Park; Ting Shi; Federico Martinón-Torres; Louis Bont; Harish Nair
Journal:  J Glob Health       Date:  2017-12       Impact factor: 4.413

10.  Lymphocyte subgroups and recurrent infections in children with Down syndrome - a prospective case control study.

Authors:  Maha Mitwalli; Yahya Wahba; Ali Shaltout; Mona Gouida
Journal:  Cent Eur J Immunol       Date:  2018-10-30       Impact factor: 2.085

View more
  1 in total

1.  Overexpression of the Hsa21 Transcription Factor RUNX1 Modulates the Extracellular Matrix in Trisomy 21 Cells.

Authors:  Nunzia Mollo; Miriam Aurilia; Roberta Scognamiglio; Lucrezia Zerillo; Rita Cicatiello; Ferdinando Bonfiglio; Pasqualina Pagano; Simona Paladino; Anna Conti; Lucio Nitsch; Antonella Izzo
Journal:  Front Genet       Date:  2022-03-10       Impact factor: 4.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.